6 completed, 1 terminated. 5 Phase 3, 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 5 |
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Terminated 1 |
Follow Double-blind Placebo: new trials by email Literature Review of Double-blind Placebo trials Research Report on Double-blind Placebo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia Open-label Pitolisant, Double-blind Placebo, Double-blind Pitolisant - Idiopathic Hypersomnia | Phase 3 | Completed | Harmony Biosciences Management, Inc. | 214 | 2022-05-25 | 2026-09-25 |
| A Trial of NT-I7 in COVID-19 (SPESELPIS) Double-Blind NT-I7, Double-Blind Placebo - COVID-19 | Phase 1 | Terminated | NeoImmuneTech | 7 | 2020-11-27 | 2023-07-14 |
| A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC) Double-Blind 0.2mg CBP-307, Double-Blind Placebo, Open-label CBP-307 - Moderate to Severe Ulcerative Colitis | Phase 2 | Completed | Connect Biopharm LLC | 145 | 2019-02-27 | 2024-05-06 |
| A Study of the Efficacy and Safety of Rituximab in Participants With Systemic Sclerosis Double-Blind Placebo, Double-Blind Rituximab - Scleroderma, Systemic, Skin Sclerosis | Phase 2 / Phase 3 | Completed | Tokyo University | 56 | 2017-12-04 | 2020-02-18 |
| Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study open-label rifaximin, double-blind placebo, double-blind rifaximin - Irritable Bowel Syndrome With Diarrhea | Phase 3 | Completed | Bausch Health Americas, Inc. | 2583 | 2012-02-01 | 2017-12-12 |
| A Study of Adalimumab in Japanese Subjects With Rheumatoid Arthritis Double-blind adalimumab, Double-blind Placebo, Open-label Adalimumab - Rheumatoid Arthritis | Phase 3 | Completed | Abbott | 334 | 2009-03-01 | 2012-08-07 |
| A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis Double-blind Abatacept, Double-blind Placebo, Open-label Abatacept - Rheumatoid Arthritis | Phase 3 | Completed | Bristol-Myers Squibb | 1795 | 2002-12-01 | 2011-11-24 |
Arthritis, Rheumatoid (2) · Autoimmune Diseases (1) · COVID-19 (1) · Collagen Diseases (1) · Diarrhea (1) · Idiopathic Hypersomnia (1) · Pulmonary Fibrosis (1) · Scleroderma, Systemic (1) · Sleepiness (1)
Abbott (1) · Bausch Health Americas, Inc. (1) · Bristol-Myers Squibb (1) · Connect Biopharm LLC (1) · Harmony Biosciences Management, Inc. (1) · NeoImmuneTech (1) · Tokyo University (1)
United States (5) · Japan (2) · China (1) · Germany (1) · Pakistan (1) · Ukraine (1) · United Kingdom (1)
Ayumi Yoshizaki, MD, PhD (1) · Enoch Bortey, PhD (1) · Hiroshi Ukai, BS (1) · Suzhou Connect (1)
PMID 24441150, PMID 27338778, PMID 27528177, PMID 27795384, PMID 28589238, PMID 28932270, PMID 29329602, PMID 29708822, PMID 35136981, PMID 36922331, PMID 38279402, PMID 38294008